Lucjan S. Wyrwicz - Publications

Is uniform D2 still biologically optimal in gastric cancer? Lymphadenectomy in the immunotherapy era.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: June 14, 2026

Real-World Pattern of Care Analysis of Liver Reirradiation Among European Organisation for Research and Treatment of Cancer Members.

Journal: Clinical oncology (Royal College of Radiologists (Great Britain))

Published: May 13, 2026

Pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction cancer: KEYNOTE-859 Q-TWiST analysis.

Journal: Immunotherapy

Published: April 11, 2026

A Randomized, Nivolumab-controlled, Phase 2 and Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 09, 2026

Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: March 06, 2026

Atezolizumab with or without tiragolumab in unresectable esophageal squamous cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 19, 2026

Tislelizumab plus chemotherapy for advanced or metastatic esophageal squamous-cell carcinoma in patients with PD-L1 Tumor Area Positivity score ≥5%: a post hoc, exploratory, long-term follow-up of RATIONALE-306☆.

Journal: ESMO open

Published: February 17, 2026

Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 21, 2026

Surrogate endpoints for survival in KEYNOTE-585: neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma.

Journal: ESMO open

Published: October 03, 2025

Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: September 24, 2025

Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 19, 2025

Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up.

Journal: Advances in therapy

Published: August 13, 2025